Mylan NV (NASDAQ:MYL) – Leerink Swann decreased their FY2021 earnings per share (EPS) estimates for Mylan in a report released on Monday, October 29th. Leerink Swann analyst A. Fadia now anticipates that the company will earn $6.18 per share for the year, down from their previous forecast of $6.20. Leerink Swann currently has a “Outperform” rating and a $47.00 price objective on the stock. Leerink Swann also issued estimates for Mylan’s FY2022 earnings at $6.72 EPS.
A number of other research analysts have also recently commented on the company. Zacks Investment Research raised Mylan from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 9th. Morgan Stanley cut Mylan from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $46.00 to $36.00 in a research note on Tuesday, October 9th. BidaskClub cut Mylan from a “sell” rating to a “strong sell” rating in a research note on Tuesday, October 9th. Mizuho cut Mylan from a “buy” rating to a “neutral” rating in a research note on Friday, October 5th. Finally, ValuEngine cut Mylan from a “sell” rating to a “strong sell” rating in a research note on Thursday, October 4th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the company. Mylan currently has an average rating of “Hold” and a consensus target price of $47.73.
Mylan (NASDAQ:MYL) last released its earnings results on Wednesday, August 8th. The company reported $1.07 EPS for the quarter, missing the Zacks’ consensus estimate of $1.22 by ($0.15). The firm had revenue of $2.81 billion during the quarter, compared to the consensus estimate of $2.95 billion. Mylan had a net margin of 3.90% and a return on equity of 18.48%. The firm’s revenue was down 5.2% compared to the same quarter last year. During the same period in the prior year, the company earned $1.10 EPS.
Several large investors have recently made changes to their positions in the company. First Mercantile Trust Co. purchased a new stake in shares of Mylan during the second quarter worth about $121,000. CENTRAL TRUST Co boosted its holdings in shares of Mylan by 1,057.8% during the second quarter. CENTRAL TRUST Co now owns 5,210 shares of the company’s stock worth $188,000 after purchasing an additional 4,760 shares during the period. FTB Advisors Inc. purchased a new stake in shares of Mylan during the second quarter worth about $188,000. Reilly Financial Advisors LLC boosted its holdings in shares of Mylan by 69.4% during the third quarter. Reilly Financial Advisors LLC now owns 5,217 shares of the company’s stock worth $191,000 after purchasing an additional 2,137 shares during the period. Finally, BB&T Corp purchased a new stake in shares of Mylan during the third quarter worth about $202,000. 82.91% of the stock is currently owned by hedge funds and other institutional investors.
Mylan Company Profile
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.
Featured Story: Call Option
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.